BOLT - Bolt Biotherapeutics, Inc.
Previous close
0.5022
-0.124 -24.652%
Share volume: 0
Last Updated: Tue 24 Dec 2024 03:57:41 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
4.47%
PREVIOUS CLOSE
CHG
CHG%
$0.63
-0.12
-19.78%
Fundamental analysis
10%
Profitability
0%
Dept financing
7%
Liquidity
75%
Performance
6%
Performance
5 Days
2.56%
1 Month
-14.53%
3 Months
-12.55%
6 Months
-30.70%
1 Year
-48.65%
2 Year
-60.55%
Key data
Stock price
$0.50
DAY RANGE
$0.50 - $0.63
52 WEEK RANGE
$0.52 - $1.56
52 WEEK CHANGE
-$50.69
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Randall C. Schatzman
Region: US
Website: boltbio.com
Employees: 90
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: boltbio.com
Employees: 90
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Bolt Biotherapeutics, Inc. engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors.
Recent news